Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Long Road to the Development of Effective Therapies for the Short Gut Syndrome: A Personal Perspective

    Research output: Contribution to journalReviewResearchpeer-review

  2. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Low-fat, high-carbohydrate parenteral nutrition (PN) may potentially reverse liver disease in long-term PN-dependent infants

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Alpha-defensin DEFA1A3 gene copy number elevation in Danish Crohn's disease patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Pattern recognition receptor polymorphisms in early periodontitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lewis and AB0 blood group-phenotypes in periodontitis, cardiovascular disease, obesity and stroke

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Gasotransmitters and the immune system: Mode of action and novel therapeutic targets

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events

    Research output: Contribution to journalReviewResearchpeer-review

  • Casper Steenholdt
  • Jørn Brynskov
  • Ole Ø Thomsen
  • Lars K Munck
  • Jan Fallingborg
  • Lisbet A Christensen
  • Gitte Pedersen
  • Jens Kjeldsen
  • Bent A Jacobsen
  • Anne Sophie Oxholm
  • Jakob Kjellberg
  • Klaus Bendtzen
  • Mark A Ainsworth
View graph of relations

BACKGROUND: In Crohn's disease patients failing infliximab therapy, interventions defined by an algorithm based on infliximab and anti-infliximab antibody measurements have proven more cost-effective than intensifying the infliximab regimen.

AIM: This study investigated long-term economic outcomes at the week 20 follow-up study visit and after 1 year. Clinical outcomes were assessed at week 20.

METHODS: Follow-up from a 12-week, single-blind, clinical trial where patients with infliximab treatment failure were randomized to infliximab intensification (5 mg/kg every 4 weeks) (n = 36), or algorithm-defined interventions (n = 33). Accumulated costs, expressed as mean costs per patient, were based on the Danish National Patient Registry.

RESULTS: At the scheduled week 20 follow-up study visit, response and remission rates were similar in all study subpopulations between patients treated by the algorithm or by infliximab intensification. However, the sum of healthcare costs related to Crohn's disease was substantially lower (31 %) for patients randomized to algorithm-based interventions than infliximab intensification in the intention-to-treat population: $11,940 versus $17,236; p = 0.005. For per-protocol patients (n = 55), costs at the week 20 follow-up visit were even lower (49 %) in the algorithm group: $8,742 versus $17,236; p = 0.002. Figures were similar for patients having completed the 12-week trial as per protocol (50 % reduction in costs) (n = 45). Among patients continuing the allocated study intervention throughout the entire 20-week follow-up period (n = 29), costs were reduced by 60 % in algorithm-treated patients: $7,056 versus $17,776; p < 0.001. Cost-reduction percentages remained stable throughout one year.

CONCLUSION: Economic benefit of algorithm-based interventions at infliximab failure is maintained throughout 1 year.

Original languageEnglish
JournalDigestive Diseases and Sciences
Volume60
Issue number9
Pages (from-to)2762-70
Number of pages9
ISSN0163-2116
DOIs
Publication statusPublished - 2015

    Research areas

  • Adult, Aged, Aged, 80 and over, Algorithms, Anti-Inflammatory Agents, Non-Steroidal, Antibodies, Monoclonal, Cost-Benefit Analysis, Crohn Disease, Female, Follow-Up Studies, Health Care Costs, Humans, Infliximab, Intention to Treat Analysis, Male, Middle Aged, Precision Medicine, Single-Blind Method, Time Factors, Treatment Failure, Young Adult

ID: 45942618